🇺🇸 Dual Anti Platelet Therapy in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 10

Most-reported reactions

1. Abdominal Pain — 1 report (10%)
2. Chronic Kidney Disease — 1 report (10%)
3. Chronic Obstructive Pulmonary Disease — 1 report (10%)
4. Colitis Ischaemic — 1 report (10%)
5. Defaecation Urgency — 1 report (10%)
6. Drug Hypersensitivity — 1 report (10%)
7. Dyslipidaemia — 1 report (10%)
8. Gout — 1 report (10%)
9. Haematochezia — 1 report (10%)
10. Haemoglobin Decreased — 1 report (10%)

Source database →

Frequently asked questions

Is Dual Anti Platelet Therapy approved in United States?

Dual Anti Platelet Therapy does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Dual Anti Platelet Therapy in United States?

Biosensors Europe SA is the originator. The local marketing authorisation holder may differ — check the official source linked above.